Great Britain, green light for the AstraZeneca vaccine.
The EMA evaluates the data
Pfizer vaccine, the other 470 thousand doses arriving in Italy on board 6 aircraft
Share
December 31, 2020
Among the 30,420 participants involved in the Moderna vaccine study, 196 became ill with Covid symptoms but, of these, only 11 were part of the vaccinated group, while 185 received placebo.
Confirming for the mRNA-1273 vaccine an efficacy of 94.1% in preventing symptomatic Covid-19 and 100% against severe forms, is the publication of the results of the Phase 3 Cove study in the famous peer review journal New England Journal of Medicine.
The data had been announced by the company in late November.
More than a hundred vaccines have been developed or developed in different laboratories around the world.
But, at the moment, there are three most promising and one of them has already been approved and administered in Europe, including Italy.
This is the Pfizer-BioNtech vaccine, based on a very innovative system called "Rna".
The approval by the EMA, the European Medicines Agency, of the vaccine produced by the American company Moderna, which is based on the same technology as that of Pfizer-BioNtech, is expected, however, for January 6.
Times are more uncertain on the Oxford-Astrazeneca vaccine.
Regulatory authorities await further data and checks.